QLB: Quadratus Lumborum Block for Percutaneous Nephrostomy

Sponsor
National Cancer Institute, Egypt (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02121951
Collaborator
(none)
0
1
2
3
0

Study Details

Study Description

Brief Summary

Percutaneous nephrostomy (PCN) is one of the interventions in the radiology department in which pain control is necessary. Quadratus Lumborum (QL) block will be tried to limit the use of systemic analgesics and its accompanying untoward effects in those frail patients requiring PCN that is performed in the prone position.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Local Anesthetic infiltration
  • Procedure: Quadratus Lumborum block
  • Drug: MAC
Phase 4

Detailed Description

Quadratus Lumborum block is a novel technique in which extension into the thoracic paravertebral space may occur. QL block would seem to be able to alleviate both somatic and visceral pain so it's expected to decrease the need for systemic sedation\analgesia to a minimum.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Quadratus Lumborum Block Versus Local Anesthetic Infiltration Combined With Monitored Anesthesia Care for Percutaneous Nephrostomy
Study Start Date :
May 1, 2014
Actual Primary Completion Date :
May 1, 2014
Actual Study Completion Date :
Aug 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Local Anesthetic infiltration and MAC

Local Anesthetic infiltration with 1% lignocaine MAC with IV Midazolam Img\ml and Fentanyl 10 mic\ml

Procedure: Local Anesthetic infiltration
Lignocaine infiltration through the nephrostomy track
Other Names:
  • Lignocaine
  • Drug: MAC
    Incremental doses are given to the targed sedation and analgesia
    Other Names:
  • -Midazolam: 1 mg\ml
  • -Fentanyl: 10 mic\ml
  • Experimental: Quadratus Lumborum block and MAC

    QL block with 0.25% levobupivacaine (Chirocaine, Abbott, Ireland) and 1% lignocaine MAC with IV Midazolam Img\ml and Fentanyl 10 mic\ml

    Procedure: Quadratus Lumborum block
    A linear 12-MHz ultrasound probe will be placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this point the layers of abdominal layers starte to taper. The probe will be placed in the posterior axillary line, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL will be noticed. At the posterior border of the quadratus lumborum muscle and outside the fascia, Touhe needle will be inserted in plane and confirmed its position by injecting saline. Under ultrasound (US) guidance, local anesthetic mixure will be deposited separating the fascia
    Other Names:
  • -0.25% levobupivacaine (Chirocaine, Abbott, Ireland)
  • -1% lignocaine
  • Drug: MAC
    Incremental doses are given to the targed sedation and analgesia
    Other Names:
  • -Midazolam: 1 mg\ml
  • -Fentanyl: 10 mic\ml
  • Outcome Measures

    Primary Outcome Measures

    1. Analgesia [4 hours]

      Verbal Rating Scale is assessed for degree of pain during the procedure and after till discharge from the radiology department.

    Secondary Outcome Measures

    1. Respiratory Depression [4 hours]

      Respiratory rate and airway patency is monitored with an anesthesiologist.

    2. Sedation [4 hours]

      Ramsay Seadation Score is assessed during and after procedure till discharge

    3. Cardiovascular stability [4 hours]

      Blood pressure and Heart rate is assessed during and after procedure till discharge

    4. Patient Satisfaction [48 hours]

      Patient Satisfaction Quistionaire

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. ASA grade III and IV patients,

    2. Ureteral obstruction due to malignancy or secondary to urinary diversion after cystectomy

    Exclusion Criteria:
    1. Bleeding diathesis; INR more than than 1.5 and platelet count less than 100,000/mm3.

    2. Untreated urinary tract infection;

    3. Pre-operative haemoglobin <10 gm/dl,

    4. Severely co morbid patients

    5. Non-dilated renal collecting system

    6. Patient refusal to consent for the procedure.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Cancer Institute Cairo Old Cairo Egypt 11796

    Sponsors and Collaborators

    • National Cancer Institute, Egypt

    Investigators

    • Study Director: Dina N Abbas, M D, National Cancer Institute, Egypt
    • Principal Investigator: Ghada M Bashandy, MD, National Cancer Institute, Egypt
    • Study Chair: Wael Darwish, M D, National Cancer Institute, Egypt

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Ghada M N Bashandy, Dr, National Cancer Institute, Egypt
    ClinicalTrials.gov Identifier:
    NCT02121951
    Other Study ID Numbers:
    • Quadratus Lumborum Block
    First Posted:
    Apr 24, 2014
    Last Update Posted:
    Apr 10, 2018
    Last Verified:
    Apr 1, 2018
    Keywords provided by Ghada M N Bashandy, Dr, National Cancer Institute, Egypt
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 10, 2018